The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Congresses
Mini-Oral
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
A DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)
Cristina Saura
View presentation
Poster
Pipeline Compounds
ESMO 2026 | October 23 - 27, 2026
Tumor-agnostic
A first-in-human phase 1 dose-escalation study of DS-1471 in patients with advanced/metastatic solid tumors
Shigehiro Koganemaru
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy followed by palbociclib, endocrine therapy (ET), and dual HER2 blockade in first-line (1L) human epidermal growth factor receptor 2–positive (HER2+), hormone receptor–positive (HR+) advanced or metastatic breast cancer (mBC) and retreatment with T-DXd (DESTINY-Breast Guide)
Sarah Sammons
View presentation
Poster
Valemetostat
ESMO 2026 | October 23 - 27, 2026
Genitourinary Cancers
A phase 1 trial of valemetostat plus darolutamide in metastatic castration-resistant prostate cancer
Rana R. McKay
View presentation
Mini-Oral
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
CHARISMA: Paired-biopsy multi-omic CHAacterization reveals targetindependent ResIStance Mechanisms to Antibody-drug conjugates
Paolo Tarantino
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
Comparative evaluation of 7 artificial intelligence (AI) tools for HER2-low and ultralow scoring in breast cancer
Jean-Sébastien Frenel
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
DESTINY-Breast Respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment
Jean-Yves Pierga
View presentation
Mini-Oral
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)
Jean-François Boileau
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Colorectal Cancer Lung Cancer Tumor-agnostic
ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors
Funda Meric-Bernstam
View presentation
Oral
HER3-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer Lung Cancer Other/Multi
Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD)
Matthias Preusser
View presentation
Pages: 1  2  3  
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24